Clinical Trial Update: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Obrixtamig plus carboplatin and etoposide versus standard chemotherapy for unresectable locally advanced or metastatic extrapulmonary n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• Obrixtamig (BI 764532)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas | Phase 3 | Status: NOT_YET_RECRUITING